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 Abstract    
Objective: The aim of the study was to evaluate whether dietary intervention could reduce maternal and perinatal 
morbidity in pregnancies with one elevated 100g oral glucose tolerance test (OGTT) value. 
Material and methods: The study was conducted among patients with positive 50g glucose challenge test (GCT) 
and one elevated 100g OGTT value. Plasma glucose value of 140 mg/dL was used as the threshold to define an 
abnormal GCT result. Carpenter and Coustan criteria were used to evaluate the OGTT results. Seventy-four women 
with normal GCT values comprised group I. Ninety-nine women with one elevated 100g OGTT value who were 
given a caloric diet and 102 women with one elevated OGTT value in group III who received antenatal care with no 
special diet were randomly assigned to groups II and III, respectively. All women were followed up until the end of 
pregnancy. Poor maternal outcome was defined as: cesarean delivery performed due to cephalopelvic dispropor-
tion, failure to progress or fetal distress, preeclampsia, and/or preterm labor. Poor perinatal outcome was defined as: 
small for gestational age, large for gestational age or admission to a neonatal intensive care unit. The groups were 
compared in terms of maternal and perinatal outcomes. 
Results: The rates of macrosomia and large for gestational age incidence were significantly higher in group III as 
compared to groups I and II. When we examined the multivariate effects of the risk factors considered to be predic-
tive of poor maternal outcomes, group III was the only statistically significant risk factor (OR=3.90, 95% CI:1.95-
7.84; p=<0.001). In terms of poor perinatal outcome, one elevated OGTT value (group III) was the only significant 
risk factor (OR=2.92, 95% CI:1.56-5.46; p=<0.001). 
Conclusion: Women with one elevated OGTT value benefit from a structured program of diet therapy aimed to 
reduce adverse maternal and perinatal outcomes. 
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Introduction
The	American	College	 of	Obstetricians	 and	Gynecologists	
(ACOG)	defines	the	term	‘gestational	diabetes	mellitus’	(GDM)	
as	the	onset	or	first	recognition	ofan	abnormal	glucose	tolerance	
during	 pregnancy	 and	 recommends	 to	 screen	 pregnant	women	
with	a	two-step	approach	which	 begins	with	a	50g	oral	GCT	and	
continues	with	a	100g	oral	OGTT	for	definitive	diagnosis	[1].	The	
diagnosis	of	GDM	is	made	if	any	two	out	of	four	threshold	values	
at	100g	OGTT	are	met	or	exceeded.	One	elevated	value	of	100g	
OGTT	is	defined	as	borderline	GDM,	impaired	glucose	tolerance,	
or	mild	gestational	hyperglycemia	[2-4].	Although	certain	amount	
of	controversy	regarding	adverse	maternal	and	fetal	outcomes	in	
cases	of	one	elevated	100g	OGTT	value	has	recently	been	noted	
[4-8],	the	need	for	surveillance	and	treatment	of	women	with	one	
elevated	100g	OGTT	value	remains	the	subject	of	much	debate	
[9].
We	 aimed	 to	 design	 a	 prospective	 randomized	 controlled	
study	to	determine	maternal	and	perinatal	outcomes	of	pregnant	
women	 with	 one	 elevated	 100g	 OGTT	 value	 and	 investigate	
whether	 dietary	 intervention	 can	 reduce	maternal	 and	perinatal	
morbidity.
Material and methods
We	 conducted	 this	 prospective	 randomized	 study	 at	 Zekai	
Tahir	Burak	Women’s	Health	 and	Education	Hospital,	Ankara,	
Turkey.	During	the	study	period,	411	pregnant	women	between	24	
and	28	weeks	of	gestation	were	screened	for	GDM.	Gestational	
age	was	calculated	using	the	date	of	the	last	menstrual	period	and	
confirmed	by	the	first	trimester	sonography.	Smokers	and	women	
with	systemic	diseases,	multiple	gestations,	and	history	of	uterine	
operations	were	excluded	from	the	study.	All	study	participants	
gave	their	informed	consent	and	the	study	protocol	was	approved	
by	the	Hospital	Research	Ethics	Committee.	
The	 screening	 test	 of	 GDM	was	 performed	 in	 all	 women	
using	the	1-hour,	50g	GCT	with	a	subsequent	3-hour,	100g	OGTT	
for	 confirmation,	 if	 screened	 positive.	 Women,	 who	 showed	
a	50g	GCT	level	of	more	than	140	mg/dL,	but	less	than	200	mg/
dL,	 took	 the	100g	OGTT.	Elevated	OGTT	values	were	defined	
as	venous	plasma	glucose	of	>95,	 180,	 155,	 or	 140	mg/dL	 for	
fasting,	1-hour,	2-hour,	and	3-hour	 tests	after	 the	100g	glucose	
load,	respectively	[10].	
Among	 411	 pregnant	 women,	 there	 were	 74	 cases	 with	
normal	 50g	GCT	 (group	 I)	 and	 201	with	 one	 elevated	 OGTT	
value.	Subjects	with	one	elevated	OGTT	value	were	randomized	
into	 two	groups	by	using	 ‘the	 toss	of	 a	 coin’	method	 in	which	
99	women	were	assigned	to	group	II	and	received	personalized	
dietary	 advice	 from	 a	 qualified	 dietitian.	 The	 remaining	 102	
women	(group	III)	received	only	routine	antenatal	care	with	no	
diet	therapy.	Meal	plans	consisted	of	a	total	daily	caloric	intake	
of	22-35	kcal/kg	according	to	a	woman’s	body	mass	index	(BMI)	
and	daily	 routine	activation	with	a	minimum	of	1800	kcal	 and	
maximum	of	2200	kcal.	Meals	were	divided	into	3	main	meals	and	
3	snacks	with	a	daily	total	caloric	distribution	of	approximately	
40%	carbohydrates,	30%	proteins,	and	30%	fat.	The	diet	therapy	
was	 continued	 if	 fasting	 blood	 glucose	 was	 <95	 mg/dL,	 and	
1-hour	post	prandial	<140	mg/dL.	The	women	with	fasting	blood	
glucose	 ≥95	 or	 1-hour	 post	 prandial≥140	 mg/dl	 were	 deemed	
eligible	for	insulin	regimen.	All	women	were	followed	up	until	
the	end	of	pregnancy	and	they	all	delivered	in	our	hospital.
The	 demographic	 and	 clinical	 features	 of	 patients	 and	
newborns	 were	 compared.	 The	 demographic	 features	 included	
maternal	 age	 at	 delivery,	 obstetric	 history,	 gestational	 period,	
pregestational	 BMI,	 total	 pregnancy	 weight	 gain,	 family	
history	 for	 diabetes	 mellitus	 in	 first	 degree	 relatives,	 history	
of	 macrosomic	 infants	 (birth	 weight	 ≥4000g),	 and	 gestational	
diabetes	mellitus	during	previous	pregnancy.	
 Streszczenie
Cel pracy: Celem badania była ocena czy zastosowanie diety może zmniejszyć matczyną i perinatalną śmiertelność 
u ciężarnych z nieprawidłowym wynikiem testu obciążenia 100g glukozy (OGTT). 
Materiał i metoda: Badanie przeprowadzono wśród pacjentek z dodatnim testem z 50g glukozy (GCT) oraz 
jedną podwyższona wartością testu 100g OGTT. Poziom odcięcia nieprawidłowego testu GCT wynosił 140mg/
dl glukozy we krwi. Kryteria Carpentera i Coustan użyto dla oceny testu OGTT. Do grupy I należały 74 kobiety 
z prawidłowym wynikiem GCT. Do grupy II losowo przydzielono 99 kobiet z jednym podwyższonym wynikiem testu 
OGTT ze 100g glukozy, które otrzymały zalecenia dietetyczne. Natomiast do grupy III losowo przydzielono 102 
kobiety z podwyższonym wynikiem testu OGTT, które nie otrzymały zaleceń dietetycznych w trakcie opieki pre-
natalnej. Wszystkie kobiety podlegały kontroli aż do ukończenia ciąży. Za gorsze wyniki położnicze uznano: cięcie 
cesarskie ze względu na dysproporcję matczyno-płodową, brak postępu porodu lub objawy zagrożenia życia płodu, 
stan przedrzucawkowy i/lub poród przedwczesny. Za gorsze wyniki perinatalne uznano: SGA, LGA lub przyjęcie 
do oddziału intensywnej opieki neonatalnej. Badane grupy porównano pod względem matczynych i perinatalnych 
wyników.
Wyniki: Odsetek makrosomii i  LGA był znacząco wyższy w grupie III w porównaniu do grupy I  i  II. W analizie 
wieloczynnikowej, spośród czynników ryzyka uznanych za niekorzystne predykcyjnie dla wyników matczynych, 
tylko grupa III okazała się być istotnym statystycznie czynnikiem ryzyka (OR=3,90, 95%CI: 1,95-7,84, p<0,001). 
Pod względem wyników perinatologicznych, jedynym czynnikiem ryzyka był pojedynczy podwyższony wynik OGTT 
(grupa III), (OR=2,92, 95%CI: 1,56-5,46, p<0,001).
Wnioski: Kobiety z pojedynczym nieprawidłowym wynikiem testu OGTT mogą odnieść korzyść z zastosowania 
diety celem zmniejszenia niekorzystnych wyników matczynych i perinatalnych. 
 Słowa kluczowe: dieta cukrzycowa / cukrzyca ciążowa / test obciążenia glukozą /
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Neonatal	birth	weights	were	also	recorded.	Birth	weight	below	
the	10th	percentile	and	above	the	90th	percentile	was	categorized	
as	small-for-gestational-age	(SGA)	and	large-for-gestational-age	
(LGA),	respectively	[11]. The	incidence	of	cesarean	delivery	due	
to	cephalopelvic	disproportion,	failure	to	progress	or	fetal	distress,	
preterm	delivery	 (before	37	weeks),	preeclampsia	 (elevation	 in	
blood	 pressure	 together	 with	 proteinuria),	 and	 other	 maternal	
complications	 were	 noted.	 Adverse	 neonatal	 events,	 such	 as	
the	5-min.	Apgar	 score	<7,	hypoglycemia	 (blood	glucose	 level	
below	40mg/dl	within	2	hours	from	birth),	polycythemia	(venous	
hematocrit	 level	 above	65%,	4	 hours	 after	 birth),	 admission	 to	
a	neonatal	 intensive	care	unit	 (NICU),	and	other	complications	
were	also	recorded.
Table I.  Demographic features of groups.
Group I Group II Group III P
Age (years) 26.20±4.67 27.89±5.79 27.91±5.81 0.079
Gravida 2.18±1.37 2.08±1.35 2.04±1.29 0.796
Parity 0.97±1.11 0.72±0.97 0.73±0.95 0.183
Pregestational BMI (kg/m2 ) 26.10±2.70 26.41±2.74 26.69±3.35 0.518
Weight gain (kg) 11.77±1.88 10.38±2.22 12.46±2.30 0.059
Obstetric history for GDM 4  (5.4) 12 (12.1) 16 (15.7) 0.108
Macrosomia history 8   (10.8) 4  (4.0) 9   (8.8) 0.215
Family history for GDM 20 (27.0) 30  (30.3) 29  (28.4) 0.892
Gestational Period (days) 272.1±9.84 269.1±12.45 268.8±13.38 0.169
Values are given as mean ±standard deviation or number (percentage); 
Group I: normal 50g GCT; 
Group II: one elevated value of 100g OGTT with diet therapy; 
Group III: one elevated value of 100g OGTT without diet therapy
Table II. Pregnancy complications, delivery route of women and clinical features of newborns in groups.
Group I Group II Group III P
Cesarean section 21  (28.4) 33  (33.3) 43  (42.2) 0.148
Preeclampsia 3  (4.1) 5  (5.1) 9  (8.8) 0.364
Preterm labor 2  (2.7) 5  (5.1) 7  (6.9) 0.464
Birth weight(g) 3288±424 3222±542 3350±661 0.279
Macrosomic infants 9  (12.2) 15  (15.1) 26  (25.5) 0.048*
LGA infants 7  (9.5) 10  (10.1) 21  (20.6) 0.044#
SGA infants 1  (1.4) 2  (2.0) 3  (2.9) 0.768
NICU admission 4  (5.4) 6  (6.1) 7  (6.9) 0.923
Neonatal hypoglysemia 1  (1.4) 1  (1.0) 2  (2.0) 0.850
5. min Apgar score <7 2  (2.7) 3  (3.0) 4  (3.9) 0.891
Neonatal polycythemia 1  (1.4) 2  (2.0) 1  (1.0) 0.824
Values are given as mean ±standard deviation or number (percentage) 
*difference between the groups is significant; p=0.704 for group I-II, p=0.029 for group I-III,  p=0.044 for group II-III
# difference between the groups is significant; p=0.888 for group I-II, p=0.046 for group I-III,  p=0.040 for group II-III
Table III. The incidence of poor maternal and perinatal outcomes.
Group I Group II Group III p*
p*
I-II I-III II-III
Poor maternal outcome 26 (35.1) 43 (43.4) 59 (57.8) 0.009 0.270 0.003 0.041
Poor perinatal outcome 12 (16.2) 18 (18.2) 31 (30.4) 0.040 0.735 0.031 0.044
Values are given as number (percentage) 
*p<.0.05 is considered statistically significant
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Poor	 maternal	 outcome	 was	 defined	 as:	 cesarean	 delivery	
due	 to	 cephalopelvic	 disproportion,	 failure	 to	 progress	 or	 fetal	
distress,	 and	 pregnancy	 complications	 (preeclampsia,	 preterm	
labor).	 Poor	 perinatal	 outcome	 was	 defined	 as:	 SGA,	 LGA	 or	
NICU	admission.
Statistical	 analysis	 was	 performed	 using	 the	 Statistical	
Package	 for	 Social	 Sciences	 (SPSS,	Version	 76,	 Chicago,	 IL).	
Normality	 testing	 (Kolmogorow-Smirnow	 test)	 was	 performed	
to	 determine	 if	 data	were	 sampled	 from	 a	 normal	 distribution.	
For	 normally	 distributed	 quantitative	 variables,	 the	 difference	
between	 the	groups	was	evaluated	by	one-way	Anova	 test.	For	
the	 quantitative	 variables	 that	 were	 not	 normally	 distributed,	
the	difference	between	the	groups	was	evaluated	by	the	Kruskal	
Wallis	test.	The	chi-square	test	was	used	to	evaluate	qualitative	
variables.	 The	multivariate	 logistic	 regression	model	 and	 odds	
ratios	 (with	 95%	confidence	 intervals)	were	 used	 to	 assess	 the	
independent	value	of	 the	 factors	associated	with	poor	maternal	
and	 perinatal	 outcomes.	 P	 <0.05	 was	 accepted	 as	 statistically	
significant.
Results
Seventy-four	women	with	normal	50-g	GCT	value	constituted	
group	 I,	 while	 99	 subjects	who	 received	 diet	 therapy	 and	 122	
who	 did	 not	 receive	 any	 diet	 therapy	 comprised	 groups	 II	 and	
III,	respectively.	Demographic	features	of	the	study	participants	
are	 shown	 in	 Table	 I.	 There	 were	 no	 significant	 differences	
between	 the	 groups	 regarding	 maternal	 age,	 gravidity,	 parity,	
pregestational	BMI,	total	pregnancy	weight	gain,	historical	status	
and	gestational	period.
Although	the	rates	of	primary	cesarean	section,	preeclampsia,	
and	preterm	labor	were	higher	in	group	III	as	compared	to	I	and	II,	
the	differences	between	the	groups	were	not	statistically	significant	
(Table	 II).	As	 far	 as	 neonatal	 data	were	 concerned,	mean	birth	
weight	in	group	I	was	3288±424	g,	in	group	II	3222±542	g	and	in	
group	III	3350±661	g	without	significant	differences	(p=0.279).	
The	 incidence	of	macrosomic	 infants	was	 the	highest	 in	group	
III	(25.5%;	Table	II).	Group	III	was	significantly	different	from	
groups	I	and	II	 in	 terms	of	 incidence	of	macrosomia	(p=0.029,	
p=0.044,	 respectively;	 Table	 II).	 Groups	 I	 and	 II	 were	 similar	
with	regard	to	incidence	of	macrosomia	(p=0.704).	Incidence	of	
LGA	was	the	highest	also	in	group	III	(20.6%;	Table	II).	
Group	 III	was	 significantly	 different	 from	 groups	 I	 and	 II	
with	regard	to	the	incidence	of	LGA	infants	(p=0.046,	p=0.040,	
respectively;	Table	2).	Groups	I	and	II	were	similar	with	regard	to	
the	incidence	of	LGA	infants	(p=0.888).	We	found	no	differences	
in	 the	 number	 of	 SGA	 infants,	 NICU	 admission,	 neonatal	
metabolic	 complications	 and	 5-min.	 Apgar	 score<7	 between	
the	groups.	There	were	no	cases	of	neonatal	birth	injury	or	fetal	
anomaly,	either.
The	groups	were	also	compared	 in	 terms	of	poor	maternal	
and	 perinatal	 outcomes	 and	 the	 results	 revealed	 significant	
differences:	57.8%	of	the	‘no	diet’	group	(III)	had	poor	maternal	
outcome.	 The	 result	 was	 significantly	 higher	 than	 the	 ‘diet	
therapy’	group	(II)	or	the	‘normal	GCT’	group	(I)	(p=0.009;	Table	
III).	
The	incidence	of	poor	perinatal	outcome	was	also	higher	in	
group	III	as	compared	to	groups	I	and	II	(p=0.040;	Table	III).
When	we	examined	 the	multivariate	effects	of	 risk	 factors	
considered	to	be	effective	in	predicting	poor	maternal	outcomes,	
the	results	from	group	III	were	statistically	significant	(OR=3.90,	
95%	 CI:1.95-7.84;	 p=<0.001).	 Also,	 group	 III	 was	 the	 only	
significant	 risk	 factor	 (OR=2.92,	 95%	CI:1.56-5.46;	p=<0.001)	
for	poor	perinatal	outcome	(Table	IV).	
Discussion
The	 fact	 that	 untreated	 GDM	 and	 lesser	 degrees	 of	
hyperglycemia	 during	 pregnancy	 are	 associated	with	 increased	
maternal	 and	 neonatal	 complications	 is	 well-established	 [12].	
Thus,	the	correct	diagnosis	is	extremely	important.	However,	there	
is	no	consensus	about	the	appropriate	screening/diagnostic	test	or	
Table IV. Multivariate logistic regression analysis of risk factors for poor maternal or perinatal outcomes.
Dependent Variables
Independent Variables OR Wald p 95% CI
Maternal Outcome
Age >30 years
GDM History
Macrosomia history
Family History
BMI ≥27
Weight gain>10kg
Group I
Group II
Group III
2.25
0.29
0.53
0.58
1.75
0.44
1.00
1.39
3.90
3.11
2.72
1.35
2.88
3.47
2.01
-
0.94
14.69
0.053
0.099
0.245
0.090
0.063
0.115
-
0.333
<0.001*
1.03-4.95
0.07-1.26
0.18-1.55
0.31-1.09
0.97-3.15
0.18-1.44
-
0.71-2.73
1.95-7.84
Perinatal Outcome
Age >30 years
GDM History
Macrosomia history
Family History 
Weight gain>10kg
Group I
Group II
Group III
1.62
1.78
1.10
0.43
1.89
1.00
0.87
2.92
1.87
1.33
0.03
3.35
2.14
-
0.14
11.27
0.172
0.248
0.858
0.061
0.222
-
0.708
<0.001*
0.81-3.24
0.67-4.74
0.39-3.06
0.21-0.88
0.46-4.86
-
0.42-1.80
1.56-5.46
*p<.0.05 is considered statistically significant
©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e Nr 9/2014752
P R A C E  O R Y G I N A L N E
  położnictwo
Ginekol Pol. 2014, 85, 748-753
Mahmut Kuntay Kokanalı et al. The effect of treatment on pregnancy outcomes in women with one elevated oral glucose tolerance test value.
diagnostic	thresholds.	At	present,	much	of	the	world	uses	a	one-
step	75g,	2-hour	test,	which	was	supported	by	the	International	
Association	 of	Diabetes	 and	 Pregnancy	 Study	Groups	 in	 2010 
[13]	 and	 the	 American	 Diabetes	 Association	 in	 2011	 [14].	
On	 the	 other	 hand,	 the	 American	 College	 of	 Obstetricians	
and	 Gynecologists	 showed	 that	 there	 is	 no	 evidence	 that	 the	
identification	and	treatment	of	women	based	on	one-step	75g	test	
will	 lead	 to	 clinically	 significant	 improvement	 in	maternal	 and	
neonatal	outcomes.	Also,	it	would	lead	to	a	significant	increase	
in	healthcare	costs.	The	diagnosis	of	GDM	should	be	based	on	
a	 two-step	approach	 in	which	 the	 initial	50g	glucose	challenge	
test	 (GCT)	 is	 followed	 by	 a	 3-hour	 100g	 OGTT,	 if	 the	 GCT	
exceeds	the	thresholds	[1].	
In	our	study,	 the	 two-step	approach	was	used.	The	women	
were	initially	screened	by	measuring	plasma	glucose	1	hour	after	
a	50g	glucose	load.	Patients	with	glucose	concentration	≥140	mg/
dL,	underwent	a	100g	OGTT	on	another	day	and	the	diagnosis	
of	GDM	was	established	by	the	Carpenter	and	Coustan	criteria,	
as	recommended	by	ACOG	[15].	We	were	able	to	determine	that	
women	with	one	elevated	100g	OGTT	value	are	still	at	risk	for	
increased	maternal	morbidities	and	neonatal	 complications	 that	
are	associated	with	GDM,	although	they	do	not	meet	diagnostic	
criteria	 for	 GDM.	 Our	 results	 also	 showed	 that	 proper	 diet	
therapy	reduces	the	risk	of	poor	maternal	and	perinatal	outcomes	
in	women	with	one	elevated	100g	OGTT	value.
The	 effect	 of	 one	 elevated	100g	OGTT	value	on	maternal	
outcome	is	not	clear.	Increased	risk	of	primary	cesarean	delivery	
among	 patients	 with	 mild	 gestational	 hyperglycemia	 has	 been	
recently	confirmed	in	the	Hyperglycemia	and	Adverse	Pregnancy	
Outcome	 (HAPO)	Study,	which	 is	 a	 large	multicenter	 trial	 (15	
centers	with	approximately	25.000	women)	using	the	75g	OGTT	
[16].	The	incidence	of	primary	cesarean	delivery	or	preeclampsia	
was	 reported	 to	 be	 higher	 in	 women	 with	 one	 elevated	 100g	
OGTT	 value	 by	 Lindsay	 et	 al.	 [6].	 However,	 Vambergue	 et	
al.,	and	Forest	et	al.,	 showed	 in	 their	studies	 that	 the	 incidence	
of	 cesarean	 delivery	 and	 preeclampsia	 was	 not	 statistically	
increased	in	patients	with	only	one	elevated	value,	regardless	of	
the	 treatment	 [4,7].	 In	another	 study	by	Fassett	 et	 al.,	 cesarean	
delivery	 incidence	was	 reported	 to	not	be	significantly	 reduced	
with	diet	therapy	in	women	with	one	elevated	100g	OGTT	value	
[17].	In	our	study,	no	difference	was	observed	between	the	groups	
in	terms	of	primary	cesarean	delivery	or	preeclampsia	incidence.	
Also,	 our	 results	 are	 in	 agreement	with	 those	 of	 Fassett	 et	 al.,	
because	there	was	a	tendency	of	increased	incidence	of	cesarean	
delivery	 in	women	with	 no	 diet	 therapy	 (42.2%)	 as	 compared	
to	 the	 two	 other	 groups	 (28.4%	 and	 33.3%),	 being	 without	
statistically	significant	difference.	
The	 rate	 of	 preterm	 labor	 in	 women	 with	 one	 elevated	
OGTT	 value	 has	 been	 somewhat	 inconsistent	 in	 the	 literature.	
Lao	et	al.,	and	Jensen	et	al.,	showed	that	the	incidence	of	preterm	
birth	correlated	significantly	with	increasing	glucose	intolerance	
according	 to	 75g	OGTT	 [18,19].	A	Taiwanese	 study	 indicated	
a	significantly	 increased	risk	for	preterm	labor	as	 the	abnormal	
value	of	the	OGTT	increased	according	to	the	two-step	approach	
[20].	 However,	 a	 Turkish	 study	 including	 2029	 singleton	
pregnancies	found	that	the	incidence	of	preterm	labor	was	similar	
between	normal	GCT	and	one	elevated	OGTT	value	groups	[21].	
Our	 study	 demonstrated	 that	 preterm	 labor	 incidence	 was	 not	
statistically	 increased	 in	patients	with	only	one	 elevated	value,	
regardless	of	treatment,	as	compared	to	women	with	normal	50g	
GCT	value.
Mean	 birth	weight	 of	 newborns	 in	 all	 groups	was	 similar.	
However,	 the	 rates	 of	 macrosomic	 and	 LGA	 infants	 were	
significantly	 increased	 in	 the	 ‘no	diet’	 group	 (III)	 as	 compared	
to	 normal	GCT	 (I)	 and	 diet	 (II)	 groups.	 It	 is	 possible	 that	 one	
elevated	 100g	 OGTT	 value	 may	 predict	 increased	 insulin	
resistance	 (that	 can	 cause	 fetal	 macrosomia)	 in	 later	 stages	 of	
pregnancy.	Therefore,	diet	therapy	and	close	monitoring	of	blood	
glucose	 levels	 may	 be	 useful.	 Our	 findings	 are	 in	 agreement	
with	 those	of	Langer	et	 al.,	who	 reported	 that	 the	 incidence	of	
macrosomic	and	LGA	infants	 is	 significantly	higher	 in	patients	
with	 one	 abnormal	 OGTT	 value	 and	 that	 the	 use	 of	 diet	 and	
insulin	therapy	is	beneficial	in	reducing	the	rate	of	macrosomic	
and	LGA	infants	[5].	The	HAPO	Study	has	recently	determined	
that	the	risk	of	having	an	LGA	infant	is	greater	than	the	risk	of	
having	 a	 macrosomic	 infant	 among	 patients	 with	 gestational	
hyperglycemia	 and	 these	 associations	 were	 present	 at	 glucose	
levels	currently	lower	than	those	used	to	diagnose	GDM	[6].	In	
contrast,	Fassett	et	al.,	stated	that	medical	nutrition	therapy	and	
self-blood	 glucose	monitoring	 did	 not	 reduce	 the	 incidence	 of	
macrosomia	in	women	with	one	elevated	100g	OGTT	value	[17].	
In	 our	 study	 population,	 a	 policy	 of	 routine	 treatment	 of	
women	with	one	elevated	OGTT	value	with	diet	therapy	did	not	
reduce	the	incidence	of	NICU	admission	and	neonatal	metabolic	
complications.	 This	 is	 in	 contrast	 to	 the	 findings	 of	 Langer	 et	
al.	 [5],	but	similar	 to	Fassett	et	al.	 [17].	Langer	et	al.,	used	 the	
higher	National	Diabetes	Data	Group	criteria	for	the	diagnosis	of	
GDM,	and	thus	examined	a	group	of	women	with	higher	degrees	
of	 hyperglycemia	who	would	benefit	more	 from	 the	 treatment.	
The	 participants	 of	 the	 study	 by	 Fassett	 et	 al.,	 and	 our	 group,	
diagnosed	using	the	lower	Carpenter	and	Coustan	criteria,	would	
have	less	hyperglycemia	and	thus	show	less	or	no	benefit	from	
treatment.
Recently,	 the	 World	 Health	 Organization	 (WHO)	 has	
defined	 pregnant	 women	 who	 meet	 the	 criteria	 for	 diabetes	
mellitus	or	 impaired	glucose	 tolerance	as	having	GDM	[22].	 It	
has	 been	 well-established	 that	 diabetes-complicated	 pregnancy	
is	associated	with	adverse	maternal	and	perinatal	outcomes	and	
lesser	 degrees	 of	 glucose	 intolerance	 have	 also	 been	 shown	 to	
be	harmful	[22,	23].	The	treatment	for	gestational	diabetes	also	
reduces	the	odds	of	adverse	pregnancy	outcomes	[22].	Thus,	the	
importance	of	diagnosis	and	treatment	approaches	for	GDM	has	
been	highlighted	 in	 several	previous	 studies.	Szymanska	et	 al.,	
presented	a	study	in	which	they	aimed	to	examine	the	influence	
of	diagnostic	time	on	the	pregnancy	outcome	among	patients	with	
gestational	diabetes	and	found	that	diagnosis	of	GDM	during	the	
recommended	 period	 (between	 24	 and	 28	 weeks	 of	 gestation)	
decreases	the	prevalence	of	LGA	as	compared	to	later	diagnosis	
[24].	In	another	study	that	was	conducted	in	Poland	over	a	10-year	
period,	it	was	suggested	that	as	no	reliable	method	of	identifying	
subjects	at	increased	GDM	risk	was	found,	all	pregnant	women	
should	undergo	screening	for	GDM	[25]	and	that	proper	nutrition	
therapy	plays	an	important	role	in	managing	GDM.	Most	women	
with	GDM	 are	 treated	 by	 diet	 therapy	 alone.	 In	 a	 prospective	
randomized	trial	reported	by	Cypryk	et	al.,	the	authors	concluded	
that	both	high-	and	 low-carbohydrate	diets	were	effective,	 safe	
and	 tolerable	 treatment	 in	 GDM	 [26].	 Similarly,	 in	 a	 recent	
review	comparing	the	effectiveness	of	GDM	treatment	with	usual	
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antenatal	care,	Falavigna	et	al.,	stated	that	treatment	of	GDM	was	
effective	in	reducing	adverse	pregnancy	outcomes	[27].	
Conclusion
In	 conclusion,	 although	 women	 with	 one	 elevated	 OGTT	
value	 do	 not	 meet	 diagnostic	 criteria	 for	 GDM,	 they	 are	
probably	at	risk	of	increased	maternal	morbidities	and	neonatal	
complications	 associated	 with	 GDM.	 Diet	 therapy	 and	 close	
monitoring	of	the	blood	glucose	levels	may	be	enough	in	women	
with	one	elevated	100g	OGTT	value	to	decrease	poor	maternal	
and	 perinatal	 outcomes	 to	 near	 baseline	 levels.	 Further	 studies	
with	 larger	 sample	 are	needed	 to	determine	 the	 significance	of	
this	 follow-up	 program	 for	 antenatal	 care	 of	 women	with	 one	
elevated	100g	OGTT	value.	
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